-

06:14:06 AM

BIIB Stock News

BIIB - Biogen Inc

08/03/22 7:32 PM

Nasdaq : BIIB

EISAI PRESENTS NEW FINDINGS ON LECANEMAB'S INVESTIGATIONAL SUBCUTANEOUS FORMULATION AND MODELING SIMULATION OF APOE4 GENOTYPE ON ARIA-E INCIDENCE AT THE ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFERENCE (AAIC) 2022

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Michel Vounatsos, "Biogen") announced that Eisai presented new findings on a subcutaneous

RHEA-AI

neutral

07/28/22 7:30 AM

Nasdaq : BIIB

clinical trial

The New England Journal of Medicine Publishes Positive Phase 2 Data on Litifilimab (BIIB059) in Cutaneous Lupus Erythematosus

Results from Phase 2 LILAC study showed litifilimab significantly reduced skin disease activity in people with cutaneous lupus erythematosus (CLE) compared to placebo as measured by the primary endpoint Biogen is also evaluating litifilimab in systemic lupus erythematosus through the Phase 3 TOPAZ

RHEA-AI

neutral

07/26/22 7:30 AM

Nasdaq : BIIB

FDA Accepts Biogen’s New Drug Application and Grants Priority Review of Tofersen for a Rare, Genetic Form of ALS

SOD1-ALS is a rare genetic form of ALS that affects approximately 330 people in the U.S., 1 it is progressive, leads to the loss of everyday functions and is uniformly fatal If approved, tofersen would be the first treatment to target a genetic cause of ALS 12-month data included in the filing show

RHEA-AI

neutral

07/05/22 7:30 PM

Nasdaq : BIIB

THE U.S. FDA ACCEPTS AND GRANTS PRIORITY REVIEW FOR EISAI'S BIOLOGICS LICENSE APPLICATION OF LECANEMAB FOR EARLY ALZHEIMER'S DISEASE UNDER THE ACCELERATED APPROVAL PATHWAY

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Michel Vounatsos, "Biogen") announced today that the U.S. Food and Drug Administration

RHEA-AI

very positive

06/22/22 9:00 AM

Nasdaq : BIIB

Biogen and Happify Health Collaborate to Support Multiple Sclerosis Patients on Digital Platform

Biogen is collaborating with Happify Health to support people living with Multiple Sclerosis Happify Health’ s platform supports the MS patient care journey, keeps patients abreast of treatment advances, helps support medication adherence, promotes holistic wellness goals, connects users with other members of the MS community, and gives them access to...

RHEA-AI

positive

06/21/22 6:37 AM

Nasdaq : BIIB

European Patent Office Grants Patent Related to TECFIDERA® (Dimethyl Fumarate)

Biogen Inc. (Nasdaq: BIIB) today announced that the European Patent Office has granted a patent that expires in February 2028 related to TECFIDERA ® (dimethyl fumarate). The

RHEA-AI

neutral

06/15/22 7:30 AM

Nasdaq : BIIB

New Data Presented at Cure SMA Reveal Residual Unmet Needs in Young SMA Patients Treated With Gene Therapy and Suggest Further Potential of Using SPINRAZA® (nusinersen)

RESPOND study is actively enrolling, with baseline characteristics reporting infants and toddlers have residual unmet medical needs in multiple areas after gene therapy; SPINRAZA treatment following gene therapy was well-tolerated Final safety data from DEVOTE Part A support the continued

RHEA-AI

neutral

06/14/22 7:30 AM

Nasdaq : BIIB

The Biogen Foundation and Community Lab Celebrates 20 Years of Serving our Communities

The Biogen Foundation has granted $70 million to help underserved communities in advancing science education, health equity, and food security More than 61,000 students have benefitted from Biogen’s free hands-on science education program through its pioneering Community Labs in Massachusetts and

RHEA-AI

very positive

06/06/22 7:30 AM

Nasdaq : BIIB

Biogen and Alectos Therapeutics Announce License and Collaboration Agreement for AL01811, a Novel GBA2 Inhibitor for the Potential Treatment of Parkinson’s Disease

AL01811 is a preclinical selective GBA2 inhibitor with first-in-class potential as an oral disease modifying treatment for Parkinson’s Disease Alectos to receive a $15 million upfront payment and is eligible to receive potential future development and commercial milestone payments CAMBRIDGE, Mass.

RHEA-AI

positive

06/03/22 8:00 AM

Nasdaq : BIIB

clinical trial

Biogen and Bio-Thera Solutions Present Positive Phase 3 Data for Tocilizumab Biosimilar Candidate at the Annual European Congress of Rheumatology (EULAR 2022)

Biogen Inc. (Nasdaq: BIIB) and Bio-Thera Solutions, Ltd. (688177.SH) today presented positive Phase 3 data for BIIB800 (BAT1806), a biosimilar candidate referencing ACTEMRA ® /ROACTEMRA ® (tocilizumab), anti-interleukin-6

RHEA-AI

neutral

1 2 3 4 5 6 7 8 9 10 Next

BIIB Data

IndustryBiological Product (except Diagnostic) Manufacturing
Websitewww.biogen.com
CeoGeorge Scangos
Security nameBiogen Inc
Issue typecs
SectorManufacturing
Sic code2836
Employees9100
Tags
- Health Technology
- Biotechnology
- Manufacturing
- Biological Product (except Diagnostic) Manufacturing
Address225 Binney St
StateMassachusetts
CityCambridge
Zip02142-1031
CountryUS
Phone17814642000

About Biogen Inc

At Biogen, mission is clear: company is pioneer in neuroscience. Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. One of the world's first global biotechnology companies, Biogen was founded in 1978 by Charles Weissmann, Heinz Schaller, Kenneth Murray and Nobel Prize winners Walter Gilbert and Phillip Sharp. Today Biogen has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first approved treatment for spinal muscular atrophy, commercializes biosimilars of advanced biologics and is focused on advancing research programs in multiple sclerosis and neuroimmunology, Alzheimer's disease and dementia, neuromuscular disorders, movement disorders, ophthalmology, neuropsychiatry, immunology, acute neurology and neuropathic pain.